Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at or call 800-767-3771 ext.  9339.

Cubist Pharmaceuticals Inc. (CBST - Analyst Report) received some encouraging news recently when the US Food and Drug Administration (FDA) accepted two of the company’s antibiotic candidates, CXA-201 and CB-315, as qualified infectious disease products (QIDP) under the Generating Antibiotic Incentives Now (GAIN) Act.

We note that Cubist Pharma applied to the FDA for granting QIDP designation to CXA-201 and CB-315 earlier in the year. The positive response from the US regulatory body would qualify CXA-201 and CB-315 for a five-year extension of Hatch-Waxman exclusivity (on approval), priority review and eligibility for fast-track designation.

We note that the GAIN act was signed into law by the US president in July 2012 as part of the FDA Safety and Innovation Act (FDASIA). The signing of the GAIN Act should benefit companies pursuing the development of novel antibiotics. Companies such as The Medicines Company (MDCO - Analyst Report) and Optimer Pharma apart from Cubist Pharma stand to benefit from the signing of the act.

We note that CXA-201 is undergoing late-stage studies for complicated intra-abdominal infections and complicated urinary tract infections caused by gram-negative bacterial infections. The QIDP status granted by the FDA is applicable to CXA-201 being developed as a therapy for complicated intra-abdominal infections. CB-315 is undergoing phase III studies for treating patients suffering from clostridium difficile-associated diarrhea (CDAD).

Apart from CXA-201 and CB-315, CB-5945 is another interesting late-stage candidate at Cubist Pharma. CB-5945 is being developed for treating opioid-induced constipation in patients with chronic non-cancer pain.

We believe that the pipeline at Cubist Pharma has to deliver since it is currently highly dependent on Cubicin (daptomycin) for growth. Cubicin is marketed in the US and several other markets for the treatment of severe bacterial infections of the skin and bloodstream. Moreover, Entereg, which was added to Cubist Pharma’s portfolio following the acquisition of Adolor Corporation, is marketed by Cubist Pharma to expedite gastrointestinal recovery following bowel resection surgery.

Furthermore, Cubist Pharma derives service revenues from its two-year agreement with Optimer for the co-promotion of Optimer’s Dificid (fidaxomicin) in the US. Dificid is marketed for treating patients suffering from CDAD.

Our Recommendation

We currently have a Neutral recommendation on Cubist Pharma. The stock carries a Zacks #3 Rank (Hold rating) in the short run.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%